Acute Myelogenous Leukemia (Clinical Trials)
Maxamine Therapy Extends Remission Duration in AML
Published in Cancer Weekly, October 7th, 1996
The results showed that treatment with Maxamine therapy continues to extend the duration of remission well beyond the length of remission reported for patients in previously published AML trials using interleukin-2 (IL-2). In addition, four patients have discontinued therapy given the extended duration of their remission and their physician's suggestion that they may have a low probability of relapse.
Based on the data generated to date, Maxim is adding patients and clinical trial sites in...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (1996-10-07)
More Articles from Cancer Weekly
- Cancer Vaccines
Irradiation Does Not Inhibit the Immunotherapeutic Response - Cancer Vaccines
Cytokine-Producing Tumors Cells Stimulate Immunity in the Central Nervous System - Antisense Technology
Compound Biological Activity Reported in Several Types of Cancer - Brain Cancer (Treatment)
Gliadel Receives FDA Clearance To Treat Cancer - Breast Cancer (Risk Factors)
Oral Contraceptives Do Not Increase Long-Term Risk of Cancer - Breast Cancer (Risk Factors)
Women Relieved Pill Does Not Increase Cancer Risk - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
